A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2002
11/21/2002	WO2002092055A1 Oxidized collagen formulations for use with non-compatible pharmaceutical agents
11/21/2002	WO2002092049A2 System for delivering cosmetics and pharmaceuticals
11/21/2002	WO2002092042A2 Pharmaceutical and cosmetic compositions against skin aging
11/21/2002	WO2002092039A1 Methods for treating or preventing diseases of the oral cavity
11/21/2002	WO2002092020A2 Compositions and methods for modulating bone mineral deposition
11/21/2002	WO2002092016A2 Therapeutic use of rank antagonists
11/21/2002	WO2002092015A2 Reagents and methods for modulating dkk-mediated interactions
11/21/2002	WO2002092008A2 Use of il-18 inhibitors for the treatement or prevention of sepsis
11/21/2002	WO2002092006A2 Nucleic acid-based compounds and methods of use thereof
11/21/2002	WO2002092003A2 Novel therapeutical quaternary ammonium compositions
11/21/2002	WO2002091995A2 Method to induce neovascular formation and tissue regeneration
11/21/2002	WO2002091993A2 Estrogen receptor modulators
11/21/2002	WO2002091992A2 Targeted delivery of drugs for the treatment of parasitic infections
11/21/2002	WO2002091990A2 Prevention of addiction in pain management
11/21/2002	WO2002091989A2 Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
11/21/2002	WO2002091988A2 Novel processes for the preparation of adenosine compounds and intermediates thereto
11/21/2002	WO2002091966A1 Kavalactone compositions and methods of use
11/21/2002	WO2002091859A1 Agent for sustaining concentration and attentiveness, and food and drink containing the agent
11/21/2002	WO2002091858A1 Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
11/21/2002	WO2002091833A1 Prebiotic and probiotic compositions and methods for their use in gut-based therapies
11/21/2002	WO2002081728A3 Quinoline inhibitors of hyak1 and hyak3 kinases
11/21/2002	WO2002079203A8 Imidazo-triazine derivatives as pde 5 inhibitors
11/21/2002	WO2002078716A3 Methylated promoters for intraductal treatment of breast cancer
11/21/2002	WO2002078615A3 Antioxidant nitroxides and nitrones as therapeutic agents
11/21/2002	WO2002076381A3 Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
11/21/2002	WO2002074981A3 Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
11/21/2002	WO2002074784A3 Novel use of a peptide class of compound for treating non neuropathic inflammatory pain
11/21/2002	WO2002074310A3 Stabilized formulation of selective ligands of retinoic acid gamma-receptors
11/21/2002	WO2002074309A3 Use of tryptophan derivatives for the specific cytostatic treatment of serotonin-producing tumors
11/21/2002	WO2002074242A3 Inhibition of toxoplasma gondii) replication by pyridinylimidazoles
11/21/2002	WO2002072798A9 Fas ligand-expressing hematopoietic cells for transplantation
11/21/2002	WO2002072137A3 Anaesthetic formulation comprising articaine
11/21/2002	WO2002072084A3 Glycyrrhetinic acid derivatives, progesterone and progesterone derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity
11/21/2002	WO2002072034A3 Chronotherapeutic dosage forms
11/21/2002	WO2002070654A3 Peptide deformylase inhibitors
11/21/2002	WO2002070513A9 Methods for the preparation of mirtazapine intermediates
11/21/2002	WO2002069976A8 Use of ovarian hormone for increasing neural stem cell number
11/21/2002	WO2002068398A9 New crystal forms of lamotrigine and processes for their preparations
11/21/2002	WO2002067953A3 Chromium/biotin treatment of dyslipidemia and diet-induced post prandial hyperglycemia
11/21/2002	WO2002067870A3 Composition and method for preventing and treating sinusoidal obstruction syndrome and radiation-induced liver disease
11/21/2002	WO2002066426A3 Fluoro oxindole derivatives as modulators of kcnq potassium channels
11/21/2002	WO2002064148A3 Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
11/21/2002	WO2002063308A3 Prediction of wound healing by urinary nitrate assay
11/21/2002	WO2002062824A3 Method of treating amyloid ? precursor disorder
11/21/2002	WO2002062343A3 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
11/21/2002	WO2002062318A3 Oral itraconazole formulations and methods of making the same
11/21/2002	WO2002062317A3 Bimodal dry powder formulation for inhalation
11/21/2002	WO2002062290A3 Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
11/21/2002	WO2002060340A9 Method for identifying maxi-k channel blockers
11/21/2002	WO2002059604A8 Diagnosis and treatment of multiple sclerosis
11/21/2002	WO2002058733A9 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
11/21/2002	WO2002058674A3 Process for preparing particles
11/21/2002	WO2002058532A3 Method for identifying ligands to lxr-receptor that stimulates pre-adipocyte differentiation and formulations thereof
11/21/2002	WO2002057246A3 Inhibitors of cruzipain and other cysteine proteases
11/21/2002	WO2002055720A3 Materials and methods relating to protein aggregation in neurodegenerative disease
11/21/2002	WO2002055514A3 Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators
11/21/2002	WO2002055089B1 Immunoassay technique using multispecific molecules
11/21/2002	WO2002053528A8 Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines
11/21/2002	WO2002051264A3 Nutritional composition with health promoting action containing oligo-saccharides
11/21/2002	WO2002049649A3 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2)
11/21/2002	WO2002049629A8 Methods for reducing chronic stress in mammals
11/21/2002	WO2002046152A3 Coniosetin and derivatives thereof, method for producing the same and use thereof
11/21/2002	WO2002043785A3 Intraocular implants for preventing transplant rejection in the eye
11/21/2002	WO2002043765A3 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
11/21/2002	WO2002043718A3 Chemotherapeutic agents for the treatment of angiogenic diseases
11/21/2002	WO2002042271A3 Biphenylcarboxamides useful as lipid lowering agents
11/21/2002	WO2002036171A9 Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
11/21/2002	WO2002031201A3 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products
11/21/2002	WO2002024226A8 Photosensitisers
11/21/2002	WO2002022598A8 Quinolinone derivatives as tyrosine kinase inhibitors
11/21/2002	WO2002020091A3 Antithrombotic compositions
11/21/2002	WO2002018637A3 Diagnosis and treatment of prostate cancer
11/21/2002	WO2002014464B1 Plant-derived and synthetic phenolic compounds and plant extracts, effective in the treatment and prevention of chlamydial infections
11/21/2002	WO2002012250B1 Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
11/21/2002	WO2002011705A3 Composition for combined use of aromatase inhibitors
11/21/2002	WO2002005799A3 Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
11/21/2002	WO2001099376A3 Arylsulfatase-inhibitors in deodorants and antiperspirants
11/21/2002	WO2001087350A3 Treatment of human papillomavirus (hpv)-infected cells
11/21/2002	WO2001042273A9 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
11/21/2002	WO2001030338A8 6-methoxy-2-naphthylacetic acid prodrugs for treating inflammation
11/21/2002	WO2001019397A9 Methods and compositions utilizing rad51
11/21/2002	US20020173736 Plaster containing 4-biphenylacetic acid
11/21/2002	US20020173669 Steroid hormone products and methods for preparing them
11/21/2002	US20020173663 Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma; benzisoxazole compounds; e.g. ((5,7-dipropyl-3-trifluoromethyl-1,2-benzisoxazol-6-yl)oxy)acetic acid, methyl ester
11/21/2002	US20020173662 Parasiticidal pyrazoles
11/21/2002	US20020173661 Phosphodiesterase-4 (PDE4); thiazole-containing pyridine (N-oxide) compounds; 4-(2-(3,4-Bis(difluoromethoxy)phenyl)-2-(5-(2-(1-hydroxy-1 -methyl)ethyl)thiazolyl)ethyl)pyridine N-oxide for example
11/21/2002	US20020173658 Administering to a mammal a substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines to reduce the levels of tumor necrosis factor-alpha to treat autoimmune diseases
11/21/2002	US20020173657 Method for the synthesis of quinoline derivatives
11/21/2002	US20020173656 Guanidine and amidine derivatives as factor Xa inhibitors
11/21/2002	US20020173655 Thioether substituted imidazoquinoline or tetrahydroimdazoquinoline compounds induce the biosynthesis of cytokines such as interferon and useful for treating viral disease in an animal
11/21/2002	US20020173654 Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor, and useful as viricides and antitumor agents
11/21/2002	US20020173648 Use in the treatment of PDE4 and TNF mediated diseases
11/21/2002	US20020173647 Polymorphic/pseudopolymorphic forms of arginine salt of 3-(4-(2-(phenoxazin-10-yl)ethoxy)phenyl)-2-ethoxypropanoic acid
11/21/2002	US20020173646 Quinazoline derivatives and pharmaceutical compositions containing them
11/21/2002	US20020173645 Acylating a 2-aryl-6-alkoxy-benzo(b)thiophene with a p-(tertiaryaminoethoxy)benzoic acid hydrohalide salt or the corresponding benzoyl halide in presence of a boron trihalide
11/21/2002	US20020173641 Nucleotide sequences coding polypeptides for use in human therapeutics, pharmacology and diagnostics
11/21/2002	US20020173638 Nucleotide sequences coding polypeptide for use in the treatment, diagnosis and prevention of ovarian cancer
11/21/2002	US20020173586 Thermogelling biodegradable aqueous polymer solution
11/21/2002	US20020173551 Bupropion to treat viral diseases
11/21/2002	US20020173550 Tetrahydrocannabinol; side effect reduction

1 ... 5643 5644 5645 5646 5647 5648 5649 5650 5651 5652 5653 5654 5655 5656 5657 5658 5659 5660 5661 5662 5663 ... 7860